Appointment dossier — Prostate Adenocarcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Prostate Adenocarcinoma
- Carboplatin — Review evidence · 0 positive · PMID 37485216
- Cisplatin — Review evidence · 0 positive / 1 negative-mixed · PMID 18408396
- Durvalumab — Review evidence · 0 positive · PMID 37485216
- Etoposide — Review evidence · 0 positive / 1 negative-mixed · PMID 37485216, 18408396
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT06235151 · Phase 3 — Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer (United States)
- NCT06931340 · Phase 3 — Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial (United States)
- NCT05168618 · Phase 2 — Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer (United States)
- NCT05691465 · Phase 2 — Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (United States)
- NCT05616650 · Phase 2 — Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor (United States)
- NCT06330805 · Phase 2 — Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer (United States)
- NCT07150715 · Phase 2 — Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma (United States)
- NCT04734730 · Phase 2 — Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (United States)
- NCT06044857 · Phase 1 — PSMA PET Response Guided SabR in High Risk Pca (United States)
- NCT06141993 — ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials (United States)
- NCT06850545 — Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer (Finland)
- NCT05931419 — High-Risk prostatE Cancer radiatiOn Versus surgERy (Netherlands)
- NCT05852041 · Early Phase 1 — rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance (United States)
- NCT05001477 — Customized TULSA-PRO Ablation Registry (United States)
- NCT04146077 — Active Surveillance for Low Risk Prostate Cancer (Russia)
- NCT07341737 · Phase 1 / Phase 2 — SL-28 for Advanced Solid Tumours (Australia)
- NCT06943521 · Phase 1 / Phase 2 — A Study of MT-4561 in Patients With Various Advanced Solid Tumors (United States)
- NCT04969315 · Phase 1 / Phase 2 — TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors (United States)
Most-relevant first: trials that name Prostate Adenocarcinoma, then broader trials you may still qualify for. 185 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT06235151), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?